Samjin Pharm Cash Flow Conversion Efficiency
Samjin Pharm cash flow conversion efficiency. Based on the latest financial reports, Samjin Pharm (005500) has a cash flow conversion efficiency ratio of -0.005x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-1.43 Billion ≈ $-969.50K USD) by net assets (₩264.51 Billion ≈ $179.25 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Samjin Pharm (2013–2024)
Cash flow conversion efficiency of Samjin Pharm from 2013 to 2024. This chart illustrates how Samjin Pharm's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Samjin Pharm share price for real-time trading data and today's change.
Samjin Pharm Cash Flow Conversion Ratio Explained
Samjin Pharm cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Samjin Pharm Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Samjin Pharm ranked by their cash flow conversion efficiency. Also see 005500 stock market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ZKH Group Limited
NYSE:ZKH
|
0.079x |
|
Bursa De Valori Bucuresti SA
RO:BVB
|
0.021x |
|
Sriracha Construction Public Company Limited
BK:SRICHA
|
0.699x |
|
MEDICLIN Aktiengesellschaft
XETRA:MED
|
0.097x |
|
Vina San Pedro
SN:VSPT
|
0.001x |
|
KJTS
KLSE:0293
|
0.018x |
|
SCH Group Bhd
KLSE:0161
|
-0.097x |
|
Paloma Acquisition Corp I Class A Ordinary Shares
NASDAQ:PALO
|
-0.001x |
Annual Cash Flow Conversion Efficiency for Samjin Pharm (2013–2024)
The table below shows the annual cash flow conversion efficiency of Samjin Pharm from 2013 to 2024. Review Samjin Pharm (005500) FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩261.66 Billion ≈ $177.32 Million |
₩38.15 Billion ≈ $25.86 Million |
0.146x | +364.31% |
| 2023-12-31 | ₩265.36 Billion ≈ $179.83 Million |
₩8.33 Billion ≈ $5.65 Million |
0.031x | -49.90% |
| 2022-12-31 | ₩275.86 Billion ≈ $186.95 Million |
₩17.29 Billion ≈ $11.72 Million |
0.063x | -38.75% |
| 2021-12-31 | ₩234.17 Billion ≈ $158.69 Million |
₩23.97 Billion ≈ $16.24 Million |
0.102x | -8.44% |
| 2020-12-31 | ₩213.46 Billion ≈ $144.66 Million |
₩23.86 Billion ≈ $16.17 Million |
0.112x | -6.60% |
| 2019-12-31 | ₩197.47 Billion ≈ $133.83 Million |
₩23.63 Billion ≈ $16.02 Million |
0.120x | -18.32% |
| 2018-12-31 | ₩205.32 Billion ≈ $139.14 Million |
₩30.08 Billion ≈ $20.39 Million |
0.147x | -23.97% |
| 2017-12-31 | ₩193.47 Billion ≈ $131.11 Million |
₩37.28 Billion ≈ $25.27 Million |
0.193x | -32.79% |
| 2016-12-31 | ₩169.69 Billion ≈ $115.00 Million |
₩48.66 Billion ≈ $32.97 Million |
0.287x | +124.21% |
| 2015-12-31 | ₩148.06 Billion ≈ $100.34 Million |
₩18.94 Billion ≈ $12.83 Million |
0.128x | -50.26% |
| 2014-12-31 | ₩126.04 Billion ≈ $85.42 Million |
₩32.41 Billion ≈ $21.96 Million |
0.257x | +293.92% |
| 2013-12-31 | ₩112.98 Billion ≈ $76.57 Million |
₩7.37 Billion ≈ $5.00 Million |
0.065x | -- |
About Samjin Pharm
Samjin Pharmaceuticals Co., Ltd. manufactures and sells medicine. It offers medicine in oral, drop, and injecting forms. The company provides over-the-counter medicines, such as Gevorin, an anti-infalammatory pain killer; Trestan, an appetite stimulant; Flaris, an anti-thrombotic agent; and Nutilin, a brain function improvement agent, as well as medicine for treatment of chronic diseases. It also… Read more